In 2006, Oktay et al. proposed a COS protocol with the co‐administration of gonadotropins and an aromatase inhibitor, letrozole to suppress estradiol elevation in patients with estrogen receptor‐positive BC (COS with letrozole).3 Here, ESR1 is linked to breast cancer.